Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parvovirus,780916,Live
29 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
29
Total Reports
1
Deaths Reported
340.0%
Death Rate
Active Ingredients
Canine Adenovirus Type 2,Toronto A/26/61,LiveCanine Distemper,Vcp258,VectorCanine Parvovirus,780916,Live
Administration Routes
SubcutaneousUnknown
Species Affected
Dog 29
Most Affected Breeds
Chihuahua 3
Retriever - Golden 3
Pit Bull 2
Spitz - German Pomeranian 2
Terrier - Jack Russell 2
Corgi - Welsh Cardigan 1
Boxer (German Boxer) 1
Shiba Inu 1
Spitz - American Eskimo Dog 1
Maltese 1
Most Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 12
Vomiting 9
Injection site pain 5
Behavioural disorder NOS 4
Injection site swelling 4
Vocalisation 4
Lameness 3
Not eating 3
Injection site lump 2
Injection site abscess 2
Diarrhoea 2
Decreased appetite 2
Outcome Breakdown
Outcome Unknown
15 (51.7%)
Recovered/Normal
13 (44.8%)
Died
1 (3.4%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.